EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients

Roberta Rosso, Marta D'Alonzo, Valentina Elisabetta Bounous iD, Silvia Actis, Isabella Cipullo iD, Elena Salerno, Nicoletta Biglia iD

Current Oncology · 21.01.2023 · 30 (2) · 1461-1472

DOI: 10.3390/curroncol30020112 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, online erschienen am 21.01.2023. Verfasst von Roberta Rosso und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gynecology and Obstetrics, Department of Surgical Sciences, School of Medicine, University of Turin, 10100 Turin, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adjuvant endocrine therapy (AET) reduces breast cancer recurrence and mortality of women with hormone-receptor-positive tumors, but poor adherence remains a significant problem. The aim of this study was to analyze AET side effects and their impact on adherence to treatment.

Methods

A total of 373 breast cancer patients treated with AET filled out a specific questionnaire during their follow up visits at the Breast Unit of our Centre.

Results

Side effects were reported by 81% of patients, 84% of those taking tamoxifen and 80% of those taking aromatase inhibitors (AIs). The most common side effect in the tamoxifen group was hot flashes (55.6%), while in the AI group it was arthralgia (60.6%). The addition of GnRH agonists to both tamoxifen and AI significantly worsened all menopausal symptoms. Overall, 12% of patients definitively discontinued AET due to side effects, 6.4% during the first 5 years and 24% during extended therapy. Patients who had previously received chemotherapy or radiotherapy reported a significantly lower discontinuation rate.

Conclusions

AET side effects represent a significant problem in breast cancer survivors leading to irregular assumption and discontinuation of therapy. Adherence to AET may be improved by trustful patient–physician communication and a good-quality care network.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleAntineoplastic Agents, HormonalChemotherapy, AdjuvantNeoplasm Recurrence, LocalTamoxifen

Stichwörter der Autor:innen

GnRH agonistadherence to treatmentadjuvant endocrine therapyaromatase inhibitorsbreast cancerquestionnaireside effectstamoxifen

Substanzen

Antineoplastic Agents, HormonalTamoxifen

Autor:innen und Institutionen

  • Division of Gynecology and Obstetrics, Department of Surgical Sciences, School of Medicine, University of Turin, 10100 Turin, Italy.

ORCID-Profile: Valentina Elisabetta Bounous, Isabella Cipullo, Nicoletta Biglia

Zitieren

APA

Rosso, R., D'Alonzo, M., Bounous, V. E., Actis, S., Cipullo, I., Salerno, E., & Biglia, N. (2023). Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients. Current Oncology, 30(2), 1461-1472. https://doi.org/10.3390/curroncol30020112

Vancouver

Rosso R, D'Alonzo M, Bounous VE, Actis S, Cipullo I, Salerno E, et al. Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients. Current Oncology. 2023;30(2):1461-1472. doi:10.3390/curroncol30020112

BibTeX
@article{Rosso2023,
  author = {Rosso, Roberta and D'Alonzo, Marta and Bounous, Valentina Elisabetta and Actis, Silvia and Cipullo, Isabella and Salerno, Elena and Biglia, Nicoletta},
  title = {Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients},
  journal = {Current Oncology},
  year = {2023},
  volume = {30},
  number = {2},
  pages = {1461--1472},
  doi = {10.3390/curroncol30020112}
}
Kostenlos starten →